Vaxcyte Inc [NASDAQ: PCVX] loss -4.09% on the last trading session, reaching $92.68 price per share at the time.
If compared to the average trading volume of 1.02M shares, PCVX reached a trading volume of 4303412 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Vaxcyte Inc [PCVX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PCVX shares is $151.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PCVX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Vaxcyte Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 07, 2023. While these analysts kept the previous recommendation, TD Cowen raised their target price to Outperform. The new note on the price target was released on April 18, 2023, representing the official price target for Vaxcyte Inc stock. Previously, the target price had yet another raise from $52 to $58, while Needham kept a Buy rating on PCVX stock.
The Average True Range (ATR) for Vaxcyte Inc is set at 4.85 The Price to Book ratio for the last quarter was 3.37, with the Price to Cash per share for the same quarter was set at 17.49.
Trading performance analysis for PCVX stock
Vaxcyte Inc [PCVX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.76. With this latest performance, PCVX shares dropped by -21.41% in over the last four-week period, additionally plugging by 22.84% over the last 6 months – not to mention a rise of 87.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PCVX stock in for the last two-week period is set at 27.09, with the RSI for the last a single of trading hit 20.72, and the three-weeks RSI is set at 33.49 for Vaxcyte Inc [PCVX]. The present Moving Average for the last 50 days of trading for this stock 111.16, while it was recorded at 99.80 for the last single week of trading, and 82.83 for the last 200 days.
Vaxcyte Inc [PCVX]: A deeper dive into fundamental analysis
Vaxcyte Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.88 and a Current Ratio set at 17.88.
An analysis of Institutional ownership at Vaxcyte Inc [PCVX]
There are presently around $107.22%, or 107.77%% of PCVX stock, in the hands of institutional investors. The top three institutional holders of PCVX stocks are: FMR LLC with ownership of 16.17 million shares, which is approximately 13.788%. BLACKROCK INC., holding 9.94 million shares of the stock with an approximate value of $$750.56 million in PCVX stocks shares; and BLACKROCK INC., currently with $$739.77 million in PCVX stock with ownership which is approximately 8.3552%.
